[go: up one dir, main page]

MX2016011055A - Nuevo polisacarido y usos del mismo. - Google Patents

Nuevo polisacarido y usos del mismo.

Info

Publication number
MX2016011055A
MX2016011055A MX2016011055A MX2016011055A MX2016011055A MX 2016011055 A MX2016011055 A MX 2016011055A MX 2016011055 A MX2016011055 A MX 2016011055A MX 2016011055 A MX2016011055 A MX 2016011055A MX 2016011055 A MX2016011055 A MX 2016011055A
Authority
MX
Mexico
Prior art keywords
bioconjugates
new
polisacarido
same
compositions
Prior art date
Application number
MX2016011055A
Other languages
English (en)
Other versions
MX380438B (es
Inventor
T Kowarik Michael
L Wetter Michael
J Kemmler Stefan
A Häuptle Micha
Gambillara Veronica
Mally Manuela
Original Assignee
Glycovaxyn Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycovaxyn Ag filed Critical Glycovaxyn Ag
Publication of MX2016011055A publication Critical patent/MX2016011055A/es
Publication of MX380438B publication Critical patent/MX380438B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0066—Isolation or extraction of proteoglycans from organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un nuevo polisacárido O de E. coli, O258. También se proporcionan en la presente células hospederas procarióticas que comprende enzimas (por ejemplo, glicosiltransferasas) usadas en la producción de O25B. Las células hospederas proporcionadas en la presente producen bioconjugados de O25B, en donde tales bioconjugados comprenden O25B ligado a una proteína portadora. Además, proporcionadas en la presente están composiciones, por ejemplo, composiciones farmacéuticas, que comprenden O25B y/o bioconjugados que comprenden O258. Tales composiciones pueden ser usadas como vacunas contra la infección con ExPEC, y pueden comprender, además, uno o más bioconjugados adicionales.
MX2016011055A 2014-02-24 2015-02-23 Nuevo polisacárido y usos del mismo. MX380438B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461943710P 2014-02-24 2014-02-24
PCT/EP2015/053739 WO2015124769A1 (en) 2014-02-24 2015-02-23 Novel polysaccharide and uses thereof

Publications (2)

Publication Number Publication Date
MX2016011055A true MX2016011055A (es) 2017-10-24
MX380438B MX380438B (es) 2025-03-12

Family

ID=52589386

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011055A MX380438B (es) 2014-02-24 2015-02-23 Nuevo polisacárido y usos del mismo.

Country Status (28)

Country Link
US (5) US9700612B2 (es)
EP (1) EP3110441B1 (es)
JP (2) JP6276427B2 (es)
KR (1) KR101855142B1 (es)
CN (1) CN106535927B (es)
AR (1) AR100859A1 (es)
AU (1) AU2015220723C1 (es)
CA (1) CA2940547C (es)
CL (1) CL2016002123A1 (es)
DK (1) DK3110441T5 (es)
EA (1) EA035991B9 (es)
ES (1) ES2978870T3 (es)
FI (1) FI3110441T3 (es)
HR (1) HRP20240847T1 (es)
HU (1) HUE066507T2 (es)
IL (1) IL247344B (es)
LT (1) LT3110441T (es)
MX (1) MX380438B (es)
NZ (1) NZ723328A (es)
PH (1) PH12016501671B1 (es)
PL (1) PL3110441T3 (es)
PT (1) PT3110441T (es)
RS (1) RS65631B1 (es)
SG (1) SG11201606889PA (es)
SI (1) SI3110441T1 (es)
TW (1) TWI639439B (es)
WO (1) WO2015124769A1 (es)
ZA (1) ZA201605858B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2945651T (pt) 2013-01-17 2018-06-12 Arsanis Biosciences Gmbh Anticorpo específico para mdr e. coli
PL3110441T3 (pl) 2014-02-24 2024-08-05 Glaxosmithkline Biologicals S.A. Nowatorski polisacharyd i jego zastosowania
JP2018515517A (ja) * 2015-05-13 2018-06-14 ユニバーシティ オブ ワシントンＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｗａｓｈｉｎｇｔｏｎ 尿路病原性大腸菌感染病の処置と予防のための組成物および方法
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711637D0 (en) * 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
CN108531439B (zh) * 2018-04-16 2020-04-07 南京工业大学 一种大肠杆菌基因工程菌及其构建方法与应用
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
IL286394B2 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc E. COLI O-antigen polysaccharide bioconjugates, methods for their production and methods for their use
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
CN110018253A (zh) * 2019-04-15 2019-07-16 艾美卫信生物药业（浙江）有限公司 一种生物制品中游离蛋白含量的高效液相测定方法
CN111855826B (zh) * 2019-04-24 2022-09-16 岛津企业管理（中国）有限公司 破伤风类毒素或白喉类毒素的监测方法
GB201908528D0 (en) * 2019-06-13 2019-07-31 Univ Dundee Rhamnose-polysaccharides
EP4090363B1 (en) 2020-01-16 2024-09-04 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
WO2021165847A1 (en) * 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
CN115605498A (zh) * 2020-02-23 2023-01-13 辉瑞公司（Us） 大肠杆菌组合物及其方法
CN115697396A (zh) 2020-06-18 2023-02-03 葛兰素史克生物有限公司 志贺氏菌-四价（Shigella4V）生物缀合物
MX2022015734A (es) 2020-06-25 2023-01-18 Glaxosmithkline Biologicals Sa Proteinas de exotoxina a modificadas.
JP7481585B2 (ja) 2020-09-17 2024-05-10 ヤンセン ファーマシューティカルズ，インコーポレーテッド 多価ワクチン組成物及びその使用
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
PL4252003T3 (pl) * 2020-11-30 2025-08-04 Janssen Pharmaceuticals, Inc. Sposób analityczny dla glikokoniugatów z zastosowaniem systemu oznaczania immunologicznego na bazie kapilar
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
TW202241929A (zh) 2021-01-12 2022-11-01 美商詹森藥物公司 ＦｉｍＨ突變體、其組成物及其用途
US12491237B2 (en) 2021-02-16 2025-12-09 Duke University Vaccine compositions and methods for the treatment and prevention of urinary tract infections
WO2022208430A1 (en) 2021-04-01 2022-10-06 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates
KR20240005684A (ko) 2021-04-08 2024-01-12 얀센 파마슈티칼즈, 인코포레이티드 바이오컨쥬게이트 생산 방법
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
US12014256B2 (en) 2022-01-12 2024-06-18 Dell Products L.P Polysaccharide archival storage
CN114150005B (zh) * 2022-02-09 2022-04-22 广州恩宝生物医药科技有限公司 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗
JP2026500159A (ja) * 2022-12-05 2026-01-06 ヤンセン ファーマシューティカルズ，インコーポレーテッド バイオコンジュゲート組成物およびバイオコンジュゲート産生方法
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
EP4478050A1 (en) 2023-06-12 2024-12-18 Janssen Pharmaceuticals, Inc. Method for quantifying bound acetate in glycoconjugates

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422653D0 (en) 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
AUPM399594A0 (en) 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
FI102976B1 (fi) 1994-02-28 1999-03-31 Valtion Teknillinen Menetelmä lisäkeittokemikaalien tuottamiseen ja käyttämiseen sulfaattiprosessissa
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
EP1278548A2 (en) 2000-04-18 2003-01-29 Endobiologics, Incorporated Lipopolysaccharide-conjugate vaccine for sepsis treatment
RU2189253C1 (ru) 2001-04-09 2002-09-20 Государственный научный центр прикладной микробиологии Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
DE60303591T2 (de) 2002-03-07 2007-03-01 Eidgenössische Technische Hochschule Zürich System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
CN1324134C (zh) 2003-12-22 2007-07-04 南开大学 对大肠杆菌o81型的o－抗原特异的核苷酸
CN1950397B (zh) 2004-03-30 2012-05-16 Ns基因公司 生长因子NsG33的治疗用途
PL2311972T3 (pl) 2005-05-11 2015-08-31 Eth Zuerich Rekombinowane n-glikozylowane białka z komórek prokariotycznych
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
ES2376492T3 (es) 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
JP4791866B2 (ja) 2006-03-24 2011-10-12 国立大学法人秋田大学 下痢原性大腸菌感染症の判別に用いられる固相等
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009089396A2 (en) 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugation of polypeptides using oligosaccharyltransferases
PL2257307T3 (pl) * 2008-02-20 2018-11-30 Glaxosmithkline Biologicals S.A. Biokoniugaty wytworzone z rekombinowanych n-glikozylowanych białek z komórek prokariotycznych
BRPI1014774A2 (pt) 2009-04-27 2019-04-16 Immuron Limited preparacao de imunoglobulina enriquecida anti-lps para uso no tratamento e/ou na profilaxia de um disturbio patologico
AU2010322454B2 (en) 2009-11-19 2016-05-19 Glaxosmithkline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
DK3336225T3 (da) 2010-07-16 2020-03-30 Adimab Llc Antistofbiblioteker
KR20140005892A (ko) 2010-12-10 2014-01-15 머크 샤프 앤드 돔 코포레이션 면역원성 조성물의 진탕-유도된 응집을 완화시키는 신규한 제제
WO2013034664A1 (en) * 2011-09-06 2013-03-14 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
BR112015004817A2 (pt) 2012-09-10 2017-07-04 Glycovaxyn Ag bioconjugados compreendendo antígenos modificados e seus usos
SG11201502638YA (en) 2012-10-12 2015-05-28 Glycovaxyn Ag Methods of host cell modification
EP2917351B1 (en) 2012-11-07 2018-12-19 GlaxoSmithKline Biologicals S.A. Production of recombinant vaccine in e. coli by enzymatic conjugation
ES2750525T3 (es) 2012-12-27 2020-03-26 Glaxosmithkline Biologicals Sa Procedimientos y composiciones relacionados con CRM197
PT2945651T (pt) 2013-01-17 2018-06-12 Arsanis Biosciences Gmbh Anticorpo específico para mdr e. coli
JP2016533719A (ja) 2013-10-11 2016-11-04 グリコヴァキシン アーゲー 宿主細胞改変方法
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
CN113388032A (zh) 2014-02-06 2021-09-14 X4制药(奥地利)有限责任公司 大肠杆菌特异性抗体序列
PL3110441T3 (pl) 2014-02-24 2024-08-05 Glaxosmithkline Biologicals S.A. Nowatorski polisacharyd i jego zastosowania
HUE057726T2 (hu) 2014-12-30 2022-06-28 Glaxosmithkline Biologicals Sa Fehérje glikozilálására szolgáló készítmények és módszerek
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
IL286394B2 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc E. COLI O-antigen polysaccharide bioconjugates, methods for their production and methods for their use
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
FR3098334B1 (fr) 2019-07-05 2021-07-23 Airbus Operations Sas Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef
WO2022208430A1 (en) 2021-04-01 2022-10-06 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates

Also Published As

Publication number Publication date
US10940192B2 (en) 2021-03-09
PL3110441T3 (pl) 2024-08-05
BR112016019341A2 (pt) 2018-01-16
AU2015220723B2 (en) 2017-12-14
US20200129605A1 (en) 2020-04-30
US9700612B2 (en) 2017-07-11
IL247344A0 (en) 2016-11-30
FI3110441T3 (fi) 2024-05-06
US20170340718A1 (en) 2017-11-30
US10441647B2 (en) 2019-10-15
LT3110441T (lt) 2024-04-25
DK3110441T5 (da) 2024-10-14
CA2940547C (en) 2021-01-05
RS65631B1 (sr) 2024-07-31
CA2940547A1 (en) 2015-08-27
US20230364214A1 (en) 2023-11-16
SG11201606889PA (en) 2016-09-29
AR100859A1 (es) 2016-11-09
EA035991B1 (ru) 2020-09-10
MX380438B (es) 2025-03-12
TWI639439B (zh) 2018-11-01
US12214029B2 (en) 2025-02-04
NZ723328A (en) 2018-01-26
SI3110441T1 (sl) 2024-07-31
PH12016501671A1 (en) 2016-10-03
TW201615211A (zh) 2016-05-01
JP6771499B2 (ja) 2020-10-21
AU2015220723C1 (en) 2018-04-05
EA201691478A1 (ru) 2017-02-28
HRP20240847T1 (hr) 2024-09-27
ZA201605858B (en) 2025-05-28
PH12016501671B1 (en) 2016-10-03
EA035991B9 (ru) 2020-10-21
DK3110441T3 (da) 2024-05-06
WO2015124769A1 (en) 2015-08-27
ES2978870T3 (es) 2024-09-23
US11738076B2 (en) 2023-08-29
JP2017507178A (ja) 2017-03-16
PT3110441T (pt) 2024-05-03
EP3110441A1 (en) 2017-01-04
IL247344B (en) 2020-06-30
CN106535927A (zh) 2017-03-22
HUE066507T2 (hu) 2024-08-28
JP2018087197A (ja) 2018-06-07
US20150238588A1 (en) 2015-08-27
KR20160125494A (ko) 2016-10-31
CL2016002123A1 (es) 2018-02-16
US20210154286A1 (en) 2021-05-27
CN106535927B (zh) 2019-09-20
KR101855142B1 (ko) 2018-05-08
JP6276427B2 (ja) 2018-02-07
EP3110441B1 (en) 2024-04-03
AU2015220723A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
MX2016011055A (es) Nuevo polisacarido y usos del mismo.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
MX389789B (es) Moléculas del receptor de envolvimiento quimérico.
MX2016008448A (es) Conjugados de var2csa-farmaco.
AU2015317711B2 (en) Compositions comprising recombinant Bacillus cells and another biological control agent
EP4293033A3 (en) Alpha (1,2) fucosyltransferase syngenes for use in the production of fucosylated oligosaccharides
AU2017246458A1 (en) Cell-free production of ribonucleic acid
CL2018000432A1 (es) Vacunas terapéuticas contra el hpv18
BR112017016338A2 (pt) produção de glicosídeos de esteviol em hospedeiros recombinantes
MY188541A (en) Besifloxacin for the treatment of resistant acne
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
MX375786B (es) Biosintesis microbiana de ergotioneina.
EA201692031A1 (ru) Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2016022377A3 (en) Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen
BR112016025792A2 (pt) meios e processos para tratamento de cmv
AU2014227660A8 (en) Ceftolozane antibiotic compositions
MY193444A (en) Cell-free production of ribonucleic acid
MX378857B (es) Celulas huespedes modificadas y usos de las mismas.
MX2018002061A (es) Soluciones de glicosidos de esteviol.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
MX385886B (es) Macromoleculas estrellas compatibles con tensoactivos.
IL246525B (en) Pomegranate derived cell culture and methods for preparing and using the same
MX2015006986A (es) Solucion de trombina y metodos de uso de esta.